Menu Search
Equities

Beta Drugs Ltd

BETA:NSI

Beta Drugs Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)2,105.75
  • Today's Change35.75 / 1.73%
  • Shares traded2.00k
  • 1 Year change+72.90%
  • Beta1.1742
Data delayed at least 15 minutes, as of Nov 13 2024 05:46 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Beta Drugs Ltd grew revenues 30.21% from 2.27bn to 2.96bn while net income improved 18.62% from 307.19m to 364.37m.
Gross margin39.95%
Net profit margin12.25%
Operating margin16.70%
Return on assets15.42%
Return on equity25.40%
Return on investment23.35%
More ▼

Cash flow in INRView more

In 2024, Beta Drugs Ltd increased its cash reserves by 49.41%, or 94.69m. The company earned 309.30m from its operations for a Cash Flow Margin of 10.46%. In addition the company used 139.72m on investing activities and also paid 74.90m in financing cash flows.
Cash flow per share53.11
Price/Cash flow per share41.02
Book value per share188.13
Tangible book value per share182.63
More ▼

Balance sheet in INRView more

Beta Drugs Ltd has a Debt to Total Capital ratio of 9.53%, a higher figure than the previous year's 4.27%.
Current ratio2.15
Quick ratio1.59
Total debt/total equity0.1054
Total debt/total capital0.0953
More ▼

Growth rates in INR

Year on year, growth in earnings per share excluding extraordinary items increased 18.62%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
EPS growth(5 years)32.46
EPS (TTM) vs
TTM 1 year ago		17.97
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.